Combined dexmedetomidine-esketamine administration
Phase 3
Combined dexmedetomidine-esketamine administration is one of 11 therapeutic programs targeting Stricture. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
11 competitors in Stricture
#DrugCompanyPhaseTrials
1Humira
NovartisApproved
Omvoh
Eli LillyApproved
Taxol
TevaApproved
Trexall
Jazz PharmaceuticalsApproved
Velban
Eli LillyApproved
Nexium
DDexcel Pharma Technologies Ltd.
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Combined dexmedetomidine-esketamine administration
PPeking University First Hospital
Phase 3
Pulmicort
SSalix
Preclinical
Rapamycin
MMaastricht Radiation Oncology
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]
- Company
- PPeking University First Hospital